This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Beerepoot, L. V. Articles by Voest, E. E. Search for Related Content PubMed PubMed Citation Articles by Beerepoot, L. V. Articles by Voest, E. E.

Recombinant Human Angiostatin by Twice-Daily Subcutaneous Injection in Advanced Cancer

A Pharmacokinetic and Long-Term Safety Study¹

Department of Medical Oncology, University Medical Center Utrecht 3508 GA, the Netherlands [L. V. B., P. O. W., G. G., B. A. Z., F. S., M. F. B. G. G., E. E. V.], and EntreMed Inc., Rockville, Maryland 20850 [W. E. F., B. K. L. S., C. S.]

ABSTRACT

Purpose: A clinical study was performed to evaluate the pharmacokinetics (PK) and toxicity of three dose levels of the angiogenesis inhibitor recombinant human (rh) angiostatin when administered twice daily by s.c. injection.

Experimental Design: Eligible patients had cancer not amenable to standard treatments. Three groups of 8 patients received 7.5, 15, or 30 mg/m²/day divided in two s.c. injections for 28 consecutive days followed by a 7-day washout period. PK assessment was done at days 1 and 28. Thereafter, in absence of toxicity or a 100% increase in tumor size, treatment was continued without interruption.

Results: Median age was 53 years (range, 43–75), male:female ratio 10:14, Eastern Cooperative Oncology Group performance 0–1. At the range of doses evaluated, serum PK of all 24 of the patients showed linear relation between dose and area under the curve_(0-) and C_max (reached after 2 h). Thirteen of 24 patients developed erythema at injection sites (11 patients, CTC grade 1; 2 patients, CTC grade 2) without pain or itching, spontaneously resolving within 2–3 weeks of treatment. Two patients went off study after developing hemorrhage in brain metastases, and 2 patients developed deep venous thrombosis. No other relevant treatment-related toxicities were seen, even during prolonged treatment. A panel of coagulation parameters was not influenced by rhAngiostatin treatment. Long-term (>6 months) stable disease (<25% growth of measurable uni- or bidimensional tumor size) was observed in 6 of 24 patients. Five patients received rhAngiostatin treatment for >1 year (overall median time on treatment 99 days).

Conclusions: Long-term twice-daily s.c. treatment with rhAngiostatin is well tolerated and feasible at the selected doses, and merits additional evaluation. Systemic exposure to rhAngiostatin is within the range of drug exposure that has biological activity in preclinical models.

This article has been cited by other articles:

				T. Levchenko, N. Veitonmaki, A. Lundkvist, H. Gerhardt, Y. Ming, K. Berggren, A. Kvanta, R. Carlsson, and L. Holmgren Therapeutic antibodies targeting angiomotin inhibit angiogenesis in vivo FASEB J, March 1, 2008; 22(3): 880 - 889. [Abstract] [Full Text] [PDF]

				L. Holmgren, E. Ambrosino, O. Birot, C. Tullus, N. Veitonmaki, T. Levchenko, L.-M. Carlson, P. Musiani, M. Iezzi, C. Curcio, et al. A DNA vaccine targeting angiomotin inhibits angiogenesis and suppresses tumor growth PNAS, June 13, 2006; 103(24): 9208 - 9213. [Abstract] [Full Text] [PDF]

				A. Kurup, C.-W. Lin, D. J. Murry, L. Dobrolecki, D. Estes, C. T. Yiannoutsos, L. Mariano, C. Sidor, R. Hickey, and N. Hanna Recombinant human angiostatin (rhAngiostatin) in combination with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer: a phase II study from Indiana University Ann. Onc., January 1, 2006; 17(1): 97 - 103. [Abstract] [Full Text] [PDF]

				A. Bratt, O. Birot, I. Sinha, N. Veitonmaki, K. Aase, M. Ernkvist, and L. Holmgren Angiomotin Regulates Endothelial Cell-Cell Junctions and Cell Motility J. Biol. Chem., October 14, 2005; 280(41): 34859 - 34869. [Abstract] [Full Text] [PDF]

				G. A. Soff, H. Wang, D. L. Cundiff, K. Jiang, B. Martone, A. W. Rademaker, J. A. Doll, and T. M. Kuzel In vivo Generation of Angiostatin Isoforms by Administration of a Plasminogen Activator and a Free Sulfhydryl Donor: A Phase I Study of an Angiostatic Cocktail of Tissue Plasminogen Activator and Mesna Clin. Cancer Res., September 1, 2005; 11(17): 6218 - 6225. [Abstract] [Full Text] [PDF]

				T. Chavakis, A. Athanasopoulos, J.-S. Rhee, V. Orlova, T. Schmidt-Woll, A. Bierhaus, A. E. May, I. Celik, P. P. Nawroth, and K. T. Preissner Angiostatin is a novel anti-inflammatory factor by inhibiting leukocyte recruitment Blood, February 1, 2005; 105(3): 1036 - 1043. [Abstract] [Full Text] [PDF]

				M. F. B. G. Gebbink, E. E. Voest, and A. Reijerkerk Do antiangiogenic protein fragments have amyloid properties? Blood, September 15, 2004; 104(6): 1601 - 1605. [Abstract] [Full Text] [PDF]